FDA expresses doubts about evidence on anemia drugs

09/10/2007 | Wall Street Journal (free content), The

The FDA discovered "important deficiencies" in data that support the beneficial effects of anemia treatment drugs Epogen and Aranesp made by Amgen and Procrit made by Johnson & Johnson. Studies that support quality-of-life improvement claims are limited and may not comply with current regulatory requirements, the FDA commented. More research is required to develop safer dosing recommendations, according to the FDA.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN